🚀Day 2 #ESMO26 Upper GI oral abstracts, summary results
🟢Paclitaxel + tovecimig ( vs paclitaxel) in 2L of advanced BTC improved ORR and PFS
🟢Adjuvant GemCis vs capecitabine in BTC, DFS median 2.14 vs. 1.49 years, log-rank p=0.097
🟣STRIDE ± L + TACE (EMERALD-3), stable liver function over treatment period and comparable safety regardless of baseline liver function
🟣BGB-B2033 (GPC3 x 4-1BB bispecific antibody) monotherapy in advanced HCC (phase I): promising ORR, further development
#cancer #oncology #MedX #GI #gastrointestinal #biliary #liver #hcc #cholangiocarcinoma @OncoAlert
49 浏览 · 0 赞 · 0 转发 · 0 回复
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for taxane-pretreated patients with advanced or metastatic gastroesophageal adenocarcinoma–Final results of the phase III IKFs602/AIO RAMIRIS Study
https://esmocongress.esmo.orgDESTINY-Breast11: MRI-assessed objective responses during neoadjuvant treatment (NAT) with trastuzumab deruxtecan (T-DXd) followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (
https://esmocongress.esmo.orgDurvalumab (D) plus carboplatin/paclitaxel (CP) followed by D with or without olaparib (O) in advanced/recurrent endometrial cancer (a/rEC): Interim overall survival (OS) and safety from the randomised phase 3 DUO-E/GOG-3041/ENGOT-EN10 stud
https://esmocongress.esmo.org来源：Erman Akkus · x.com